Zhen Zeng

Mrs. Zhen Zeng

UQDI
orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 September 2018 in Frontiers in Medicine
Verified
Journal Article
Open access
PDF file
PKPaula T. Kuo
Paula T. Kuo
ZZZhen Zeng
Zhen Zeng
NSNazhifah Salim
Nazhifah Salim
SMStephen Mattarollo
Stephen Mattarollo
JWJames W. Wells
James W. Wells
Graham LeggattGraham Leggatt
Graham Leggatt
Chemokines and their receptors play an important role in the recruitment, activation and differentiation of immune cells. The chemokine receptor, CXCR3, and its ligands, CXCL9, CXCL10, and CXCL11 are key immune chemoattractants during interferon-induced inflammatory responses. Inflammation of the skin resulting from infections or autoimmune disease drives expression of CXCL9/10/11 and the subsequent recruitment of effector, CXCR3+ T cells from the circulation. The relative contributions of the different CXCR3 chemokines and the three variant isoforms of CXCR3 (CXCR3A, CXCR3B, CXCR3alt) to the inflammatory process in human skin requires further investigation. In skin cancers, the CXCR3 receptor can play a dual role whereby expression on tumor cells can lead to cancer metastasis to systemic sites while receptor expression on immune cells can frequently promote anti-tumor immune responses. This review will discuss the biology of CXCR3 and its associated ligands with particular emphasis on the skin during inflammation and carcinogenesis.

Verified
Journal Article
Open access
PDF file
ZZZhen Zeng
Zhen Zeng
HCHui Yi Chew
Hui Yi Chew
Jazmina Libertad Gonzalez CruzJazmina Libertad Gonzalez Cruz
Jazmina Libertad Gonzalez Cruz
Graham LeggattGraham Leggatt
Graham Leggatt
JWJames Wells
James Wells
T cells play a key role in tumour surveillance, both identifying and eliminating transformed cells. However, as tumours become established they form their own suppressive microenvironments capable of shutting down T cell function, and allowing tumours to persist and grow. To further understand the tumour microenvironment, including the interplay between different immune cells and their role in anti-tumour immune responses, a number of studies from mouse models to clinical trials have been performed. In this review, we examine mechanisms utilized by tumour cells to reduce their visibility to CD8+ Cytotoxic T lymphocytes (CTL), as well as therapeutic strategies trialled to overcome these tumour-evasion mechanisms. Next, we summarize recent advances in approaches to enhance CAR T cell activity and persistence over the past 10 years, including bispecific CAR T cell design and early evidence of efficacy. Lastly, we examine mechanisms of T cell infiltration and tumour regression, and discuss the strengths and weaknesses of different strategies to investigate T cell function in murine tumour models.

28 April 2021 in Cancers
Verified
Journal Article
Open access
PDF file
ZZZhen Zeng
Zhen Zeng
MVMargaret Veitch
Margaret Veitch
GKGabrielle A. Kelly
Gabrielle A. Kelly
ZTZewen Tuong
Zewen Tuong
Jazmina Libertad Gonzalez CruzJazmina Libertad Gonzalez Cruz
Jazmina Libertad Gonzalez Cruz
JWJames Wells
James Wells
Ultraviolet (UV) radiation-induced tumours carry a high mutational load, are highly immunogenic, and often fail to grow when transplanted into normal, syngeneic mice. The aim of this study was to investigate factors critical for the immune-mediated rejection of cutaneous squamous cell carcinoma (SCC). In our rejection model, transplanted SCC establish and grow in mice immunosuppressed with tacrolimus. When tacrolimus is withdrawn, established SCC tumours subsequently undergo immune-mediated tumour rejection. Through the depletion of individual immune subsets at the time of tacrolimus withdrawal, we established a critical role for CD8+ T cells, but not CD4+ T cells, γδ T cells, or NK cells, in driving the regression of SCC. Regression was critically dependent on IFN-γ, although IFN-γ was not directly cytotoxic to SCC cells. IFN-γ-neutralisation abrogated SCC regression, significantly reduced CD8+ T cell-infiltration into SCC, and significantly impaired the secretion of CXCL9, CXCL10 and CCL5 within the tumour microenvironment. A strong positive correlation was revealed between CXCL10 expression and CD8+ T cell abundance in tumours. Indeed, blockade of the CXCL10 receptor CXCR3 at the time of tacrolimus withdrawal prevented CD8+ T cell infiltration and the regression of SCC. Chimeric models revealed an important role for immune cells as producers of IFN-γ, but not as recipients of IFN-γ signals via the IFN-γ receptor. Together, these findings suggest a key role for IFN-γ in driving the expression of chemokines within the tumour environment essential for the destruction of established SCC by CD8+ T cells.

23 August 2023 in Pigment Cell & Melanoma Research
Verified
Journal Article
Open access
ZZZhen Zeng
Zhen Zeng
HNHung Long Ngo
Hung Long Ngo
MPMartina Proctor
Martina Proctor
Helen RizosHelen Rizos
Helen Rizos
RDRiccardo Dolcetti
Riccardo Dolcetti
Brian GabrielliBrian Gabrielli
Brian Gabrielli
Treatment of melanomas with targeted and immunotherapies has proven effective, but resistance to both treatments is a common outcome leaving a high proportion of patients without effective alternative treatment options. Replication stress is a common feature of melanomas, and this is effectively targeted using a combination of checkpoint kinase 1 (CHK1) inhibitor and low‐dose hydroxyurea (LDHU). This combination also promotes inflammatory and anti‐tumour immune responses in vivo. Melanoma cell lines resistant to BRAF inhibitor (BRAFi) or immune checkpoint inhibitors (ICI) retain their sensitivity to CHK1i + LDHU, with sensitivity similar to that of parental tumours. In vivo, BRAFi‐resistant and BRAFi‐sensitive parental tumours produce an identical immune response with treatment.

29 May 2025 in Cancers
Verified
Journal Article
Open access
PDF file
NGNicole Lisa Li-Ann Goh
Nicole Lisa Li-Ann Goh
NRNur Jannah Abdul Rahim
Nur Jannah Abdul Rahim
RBRituparna Bhatt
Rituparna Bhatt
SOSi En Ong
Si En Ong
KLKhai Yee Lim
Khai Yee Lim
Brian GabrielliBrian Gabrielli
Brian Gabrielli
Background/Objectives: Melanoma has a rising incidence worldwide. Current treatments are effective, although the development of resistance is common. A novel anti-cancer treatment using checkpoint kinase 1 inhibitor (CHK1i), SRA737, in combination with low-dose hydroxyurea (LDHU), has been demonstrated to effectively kill tumour cells and promote an anti-tumour immune response through the treatment-induced release of pro-inflammatory chemokines and cytokines. These chemokines/cytokines modify the tumour microenvironment from an immunosuppressive to an inflamed state to recruit anti-tumour immune cells. Methods: A panel of human melanoma cell lines was assessed using a panel of chemokines and cytokine expression, and the mechanism of their regulation was investigated. Results: We demonstrate that SRA737 + LDHU upregulates pro-inflammatory chemokines in human melanoma cells in response to SRA737 + LDHU through the ATM-NF-κB signalling pathway. The increased chemokine expression corresponded to the increase in secretion of pro-inflammatory chemokines from tumour cells following SRA737 + LDHU treatment. However, inhibiting NF-κB and ATM did not affect SRA737 + LDHU-induced cell killing. Increased expression of non-NF-κB target genes with SRA737 + LDHU suggests that other transcriptional pathways are also activated and may contribute to the increasing cytokine/chemokine gene expression in response to treatment. Conclusions: SRA737 + LDHU upregulates pro-inflammatory chemokine expression through an ATM-NF-κB-dependent mechanism.

1 January 2016 in Journal of Biotechnology
Verified
Journal Article
Closed access
ZZZhen Zeng
Zhen Zeng
ZZZheng Zhou
Zheng Zhou
DWDan Wang
Dan Wang
ZWZitian Wang
Zitian Wang
HYHuali Yang
Huali Yang
RCRun-Sheng Chen
Run-Sheng Chen